Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100
about
Crystal Structure of the HIV-2 Neutralizing Fab Fragment 7C8 with High Specificity to the V3 Region of gp125Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicityProline substitution independently enhances H-2D(b) complex stabilization and TCR recognition of melanoma-associated peptidesThe MHC Class I Cancer-Associated Neoepitope Trh4 Linked with Impaired Peptide Processing Induces a Unique Noncanonical TCR ConformerInflammation-associated nitrotyrosination affects TCR recognition through reduced stability and alteration of the molecular surface of the MHC complexRelapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinityNatural killer cell tolerance persists despite significant reduction of self MHC class I on normal target cells in mice.DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responsesBiomaterials for nanoparticle vaccine delivery systems.Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.Distortion of the Major Histocompatibility Complex Class I Binding Groove to Accommodate an Insulin-derived 10-Mer PeptideTCR hypervariable regions expressed by T cells that respond to effective tumor vaccines.Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cellsTAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.Reviving virus based cancer vaccines by using cytomegalovirus vectors expressing modified tumor antigens.Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice.Going Pro to enhance T-cell immunogenicity: easy as π?Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.Cancer vaccines inducing antibody production: more pros than cons.Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects.PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine ImmunizationThe immunogenicity of a novel cytotoxic T lymphocyte epitope from tumor antigen PL2L60 could be enhanced by 4-chlorophenylalanine substitution at position 1.Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity.Pan-Specific Prediction of Peptide-MHC Class I Complex Stability, a Correlate of T Cell ImmunogenicityLipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy.Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity.Synthetic melanin bound to subunit vaccine antigens significantly enhances CD8+ T-cell responses.Structural basis for ineffective T-cell responses to MHC anchor residue-improved "heteroclitic" peptides.Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopesA potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapyEpitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma.Unexpected T-cell recognition of an altered peptide ligand is driven by reversed thermodynamics.Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires.Crystal structures of H-2Db in complex with the LCMV-derived peptides GP92 and GP392 explain pleiotropic effects of glycosylation on antigen presentation and immunogenicity.
P2860
Q27667679-F0ECD3B0-745C-43E4-A9F4-FB335F9D16EDQ27680213-7C4FB00A-BECF-47B8-9EFA-FF23EB30CCEEQ27685375-1D598864-4A68-4E6A-A986-9117788B54C2Q27703723-72471098-D269-4E11-8C63-856E055E4F17Q28481493-1FC9AF3B-C130-47D9-BB7E-9151372CBA88Q30413827-329C5CBF-ECB5-4BD5-8741-ECAEF34DE2AEQ33722187-F5A98838-99CF-4CB2-9E65-C3A0CFD3C9C0Q34127323-6874A4CF-E4A8-4CE2-8B13-7511AF6CDF2EQ34345012-AA4C76C9-DBEE-45A3-A5CC-67EF8F320EF7Q35836140-EDCCC115-4BA6-4EAD-8973-542172C58963Q35905292-270AD73B-9E68-4B02-A96A-3047706715ADQ36137249-4CBB2792-02A1-44FC-AFBE-308DAAE59FA6Q36505831-007BFB55-465E-4BD4-9F89-C2717A1BAF90Q36515165-D692F5F6-2C39-47DD-A28D-16DE4EBCEF51Q36597476-B3767906-CC98-4A7D-8C68-4713840EF574Q37129222-E244B614-E2D1-4A4F-9C71-F67030E8A75BQ37474545-067C9E30-E4EB-43C3-B610-4A631BAE7EA3Q37554718-62E190A6-1995-4AC7-8E2C-A047A0E9A5E2Q37932519-CCE2F257-70F3-45E3-83CC-3B8228D94735Q38231581-9B75E156-A55F-4C5B-8350-B09AD3564CFEQ38867768-DAAD1DBA-9491-41CE-9679-C7CA57214292Q39090059-AC084F2F-8064-45E5-B3FA-64EB2F752920Q39606015-3859545D-0452-429D-99B9-94EDFA62ADF3Q39611616-C756BD65-F060-4916-B8C9-A1DDED65F1B4Q40302175-7E3FF79D-EDE5-4299-948B-264C9D571410Q40607907-4B8B0C9C-0043-4B97-84E3-656B6DE5C55FQ41035371-679FE3F0-C31D-47C2-80C9-3FAFC7D83B54Q41620273-29DB63AE-2B0C-4076-AC45-B6C180A43CA0Q41703140-6B1BBAFA-4372-4F1D-8127-942A551EB871Q41859070-9DD701F1-9C83-4D22-88AA-2504AE05B195Q41955454-2D540FD9-FE55-4245-A0F6-8B56F27D1952Q44447688-4821EE2E-63E0-4E8C-A8C2-33CA4CAA7BB0Q46383217-5A912079-DBE2-46EA-A4F8-A493DB3EBFABQ47144276-3D13D592-F54D-40FE-8A74-176434E2C458
P2860
Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Design of agonistic altered pe ...... anoma-associated epitope gp100
@ast
Design of agonistic altered pe ...... anoma-associated epitope gp100
@en
Design of agonistic altered pe ...... anoma-associated epitope gp100
@nl
type
label
Design of agonistic altered pe ...... anoma-associated epitope gp100
@ast
Design of agonistic altered pe ...... anoma-associated epitope gp100
@en
Design of agonistic altered pe ...... anoma-associated epitope gp100
@nl
prefLabel
Design of agonistic altered pe ...... anoma-associated epitope gp100
@ast
Design of agonistic altered pe ...... anoma-associated epitope gp100
@en
Design of agonistic altered pe ...... anoma-associated epitope gp100
@nl
P2093
P1433
P1476
Design of agonistic altered pe ...... anoma-associated epitope gp100
@en
P2093
Daniel Badia-Martinez
Marianne J B van Stipdonk
Marjolein Sluijter
Rienk Offringa
P304
P356
10.1158/0008-5472.CAN-09-1724
P407
P577
2009-10-01T00:00:00Z